Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Mycobacterium tuberculosis and the response of its host
-
2. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
3. Immune response and rational development of vaccines and biomarkers
- Prof. Dr. Stefan H. E. Kaufmann
-
4. Molecular mechanisms of drug resistance in M. tuberculosis
- Dr. Daniela Cirillo
- The epidemiology of tuberculosis
-
5. The basic epidemiology of tuberculosis (TB)
- Dr. David Dowdy
-
6. Global epidemiology of TB
- Dr. Philippe Glaziou
-
7. Social determinants of tuberculosis
- Dr. Knut Lönnroth
- The control of tuberculosis
-
8. Treatment of tuberculosis
- Dr. Jean-Pierre Zellweger
-
9. The End TB Strategy towards TB elimination 1
- Dr. Mario Raviglione
-
10. The End TB Strategy towards TB elimination 2
- Dr. Mario Raviglione
-
11. Financing TB care and control
- Dr. Christopher Fitzpatrick
- Dr. Andrea Pantoja
-
12. Tuberculosis and COVID-19
- Prof. Giovanni Battista Migliori
-
13. Multidrug resistant tuberculosis (MDR-TB): an update
- Dr. Simon Tiberi
-
14. Impact of HIV on tuberculosis in the developing world and how to manage it
- Prof. Anthony D. Harries
-
16. TB in children
- Prof. Ben J. Marais
-
17. Community engagement in tuberculosis care
- Ms. Lana Syed
-
18. India: the epicentre of global TB control
- Dr. Madhukar Pai
-
19. Community engagement in TB care
- Dr. Haileyesus Getahun
- Research and development for new approaches in the control of tuberculosis
-
20. Development of new regimens for tuberculosis
- Dr. Zhenkun Ma
-
22. Pharmacometrics in tuberculosis
- Prof. Charles A. Peloquin
-
23. Extrapulmonary tuberculosis
- Dr. Scott Heysell
-
24. The role of surgery in tuberculosis management
- Dr. Richard Zaleskis
- Archived Lectures *These may not cover the latest advances in the field
-
25. The development of current treatments for tuberculosis
- Dr. Andrew Nunn
-
26. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
27. Basics of tuberculosis epidemiology
- Prof. Frank Cobelens
-
29. The international approach to the control of tuberculosis
- Dr. Mario Raviglione
-
30. Public-private mix for TB care and control
- Dr. Mukund Uplekar
Printable Handouts
Navigable Slide Index
- Introduction
- The End TB Strategy towards TB elimination
- The End TB Strategy: vision, targets and pillars
- The top 10 indicators of the End TB Strategy
- Pillar 1: integrated, patient-centred care and prevention
- Case notifications increasing but large incidence: notification gap remains
- Use of rapid molecular diagnostic tests
- Drug-resistant TB: % diagnosed and treated, and gaps
- Use of drug susceptibility testing
- Treatment of drug-susceptible TB
- MDR/RR-TB treatment coverage, 2019
- Criteria to decide on the best MDR-TB regimen
- 2018 WHO recommendations for grouping of drugs for longer MDR-TB regimens and approach
- Responding to the TB/HIV epidemic
- Facing the TB/HIV challenge
- % of population with latent TB
- Latent TB infection – WHO guidelines 2020
- BCG vaccination practice
- Pillar 2: bold polices and supportive systems
- Critical funding gaps can compromise efforts to save lives
- Policies: strong health information systems data sources for TB burden assessment
- Contribution of PPM to case notifications
- Contribution of community engagement
- WHO guidelines on TB infection prevention and control
- Universal health coverage “cube”:
- Composition of TB related costs and solutions
- Proportion with catastrophic total costs due to TB
- % TB patients and households facing catastrophic costs
- Adding a “social protection floor”
- Then COVID-19 came and, with it, more poverty and more needs
- Impact of COVID-19 on TB control
- Impact of COVID-19 on TB notifications
- Impact of COVID-19 on TB deaths
- Pillar 3: intensified research and innovation
- Innovations and research are critical to break the trajectory of the TB epidemic
- Prospects for TB elimination
- 54 low TB incidence countries
- Challenges for TB elimination in low-incidence countries
- Action framework
- Research and development
- Transformational innovations to end TB
- TB digital health applications
- Genome sequencing for DST
- Internet of things for TB
- Why investing towards ending TB?
- What is holding us back?
- Bottleneck 1: political indifference
- Bottleneck 2: financial inadequacy
- Finally, some visibility and sense of urgency high-level commitment to end TB: 2017-18
- What is the key political _x000B_recommendation today?
- Broader influences also matter
- Accountability
- 10 priority recommendations
- Thank you
Topics Covered
- Tuberculosis
- The End TB Strategy
- Rapid molecular diagnostic testing
- Drug resistant TB
- Drug susceptibility testing
- TB and HIV
- Latent TB
- BCG vaccination
- Universal health
- TB and COVID-19
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Raviglione, M. (2021, November 30). The End TB Strategy towards TB elimination 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/FMNR1700.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Mario Raviglione has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
The End TB Strategy towards TB elimination 2
Published on November 30, 2021
52 min
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everyone, this is Mario Raviglione,
I am a professor at the University of Milan where I teach global health and
I'm also an honorary professor at the Queen Mary University of London.
I used to be the director of the Global tuberculosis program at
the World Health Organization in Geneva between 2003 and 2017.
This talk is part 2 of my talk on the End TB Strategy.
0:30
As you remember from the previous talk I
addressed in that one the burden of tuberculosis,
the international targets and the progress towards them,
the challenges to be faced today and finally
the evolution of the global strategy of tuberculosis from DOTs to the End TB Strategy.
In this talk I will be speaking exclusively about
the End TB Strategy providing all details. The End TB Strategy
0:59
that as you heard in my previous part one was fully
approved by the World Health Organization in 2014 and is
a strategy that accompanies
the sustainable development goals of the United Nations, it's part of it in
a way, starting therefore in 2016 with the deadline in 2030.
In this slide you see the vision the targets of the End TB Strategy.
We have a vision of a world free of tuberculosis
of a goal of ending the epidemic which coincides
not by coincidence by the way with
the sustainable development goals/aims of ending the epidemic.
You see the three essential pillars
of the strategy that I'm going to describe in detail,
the first one is on integrated patient-centered TB care and prevention,
if you like it's more the approach to the patient, it's the care part.
Pillar 2 is on the policies instead,
and speaks of the bold policies and the supportive systems that must be in
place in a health system in a country to support the fight against tuberculosis.
Finally pillar 3,
is the one devoted to innovation and research,
at the bottom there you see four layers,
these are the four essential principles of the strategy,
so the government has to provide the stewardship and has to be accountable,
the second one is the coalition that is
necessary with the civil society and the communities,
the third one is the protection,
the promotion of human rights of ethical behavior and finally of equity.
Finally the last point there, the last principle is that of
the adaptation of the strategy and the targets at the country level locally if you like,
and the global collaboration that is necessary.
On the right you have the targets,
and the targets which I have described in part 1 of
this talk and that I'm repeating and I'm focusing on those for
2030 that coincides with
the sustainable development goals for 2030 for tuberculosis are the reduction,
or number of TB deaths by 90 percent.
A reduction in incidence of tuberculosis by
80 percent and what we would like to see starting
actually in 2020 and in 2025 continuing and proceeding to 2030 is zero,
is that number a zero, no family,
no patient affected by TB should be facing catastrophic costs.
These are the main,
if you like indicators and therefore the targets related to
those indicators that define the whole philosophy of the strategy.